Skip to product information
1 of 1

Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20

Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20

Regular price $201.20 USD
Regular price $402.40 USD Sale price $201.20 USD
Sale Sold out
Shipping calculated at checkout.
Title
Quantity
Features & Benefits:
  • Hemosure's fecal occult blood test is a qualitative, sandwich dye conjugate immunoassay and employs a combination of monoclonal and polyclonal antibodies to selectively identify in human feces, as an aid in diagnosis of fecal occult blood, with a high degree of sensitivity
  • In less than 5 minutes, elevated levels of human hemoglobin as low as 0.05ugHb/ml can be detected and positive results for high levels of hemoglobin can be seen in the test as early as 1 or 2 minutes
  • Pack includes 20 fecal occult blood test cassettes and 20 home kits: Each kit includes collection tube, two collection papers, patient instructions and return envelope

The full picture

Everything Vyvata knows about this product — the score, the evidence, the FAQ, and where else to find shopper reviews. No hidden data. Every vendor is scored on the same published rubric — no brand can pay for placement. Read the rubric →

71/100
Verified

Six-dimension breakdown

Evidence
72
Formulation
68
Manufacturing
75
Safety
82
Transparency
65
Sustainability
45

Why this scored 71/100

The Hemosure iFOB (FIT) is a CLIA-waived, FDA-cleared immunochemical fecal occult blood test used broadly in real colorectal cancer screening programs. FIT has strong RCT evidence for reducing CRC mortality. The 20-test pre-pack format is oriented toward clinical use but usable at home.

Last scored: Full rubric →

Evidence & sources

The Vyvata score's Evidence dimension measures the quality of published RCT support for a product's active ingredients at the label dose. Our source hierarchy: double-blind RCTs in MEDLINE-indexed journals > single-blind RCTs > open-label trials > observational studies > mechanism papers > N=1 case studies (anecdotes). Predatory journals and manufacturer-authored studies without independent replication are weighted down.

Product-specific evidence citations for this item are embedded in the analysis text on the "Analysis" tab. For the full framework and evidence hierarchy, see the methodology page.

How to read the Evidence dimension

  • 80–100: Multiple double-blind RCTs in indexed journals directly testing this product OR the exact ingredients at the exact dose.
  • 60–79: Single double-blind RCT + supporting ingredient literature at the studied dose.
  • 40–59: Open-label trials + ingredient literature; no product-specific double-blind evidence.
  • 20–39: Ingredient literature only; no product-specific trials or trials in predatory venues.
  • 0–19: No credible evidence base or unverifiable claims.

Frequently asked questions

Auto-generated from Vyvata's scoring data for this product. For general questions about the store (shipping, returns, wholesale), see the site FAQ.

What is Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20?

Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20 is a product from Medsitis, categorized under Cancer & chronic disease screening in the Diagnostics & Testing vertical. It is scored on the Vyvata Scoring Framework — an independent 6-dimension rubric applied uniformly to every product Vyvata lists.

How does Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20 score on the Vyvata rubric?

71/100 overall — Verified tier (70–84 band). Per-dimension breakdown: Safety 82, Manufacturing 75, Evidence 72, Formulation 68, Transparency 65, Sustainability 45. Scored as of 2026-07-31.

Why did Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20 score in the Verified tier?

The Hemosure iFOB (FIT) is a CLIA-waived, FDA-cleared immunochemical fecal occult blood test used broadly in real colorectal cancer screening programs. FIT has strong RCT evidence for reducing CRC mortality. The 20-test pre-pack format is oriented toward clinical use but usable at home.

What are the strongest and weakest aspects of this product?

Strongest: Safety at 82/100 (adverse-event profile, interaction risk, and dose ceiling) and Manufacturing at 75/100 (third-party testing, GMP compliance, and facility audit status). Weakest: Transparency at 65/100 (dose disclosure vs proprietary blends, and honesty of marketing claims) and Sustainability at 45/100 (sourcing practices, packaging, and corporate practice). All six dimensions feed the overall Vyvata score; a weakness on any one dimension pulls the overall down proportionally.

Is Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20 third-party tested?

No third-party certifications (NSF, USP, ConsumerLab, or equivalent) were on record at the time of scoring. This affects the Manufacturing dimension score. The manufacturer may test internally or have obtained certification more recently — check the current product label for the most up-to-date information.

Are there higher-scoring alternatives to Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20?

The top-ranked cancer & chronic disease screening product in the Vyvata catalog is currently Hemosure® Fecal Occult Blood (iFOB or FIT) Colorectal Cancer Screening Test Kit T1-CK30T at 71/100. See the full ranked list of 3 scored products in this subcategory at https://vyvata.com/pages/best-cancer-and-chronic-disease-screening-ranked.

What does the Vyvata score mean?

The Vyvata Scoring Framework rates every listed product 0–100 across six dimensions: Evidence, Formulation, Manufacturing, Safety, Transparency, and Sustainability. Tier bands: Elite 85–100 (top-tier evidence + formulation + manufacturing), Verified 70–84 (strong on most dimensions), Standard 50–69 (solid but with weaknesses called out), Rejected 0–49 (specific failures documented). Rejected products remain listed with reasons. Full methodology at https://vyvata.com/pages/methodology.

Where can I read customer reviews for Cancer Screening Test Kit Hemosure® Fecal Occult Blood Test (iFOB or FIT) 20 Tests CLIA Waived - PRE-PACK IFOB20?

Customer reviews

Reviews on other platforms

The Vyvata score measures product integrity against a published rubric, not customer sentiment. Vyvata does not aggregate, republish, or license third-party reviews — the links below open search pages on their respective platforms.

All the data we have on this product

Every VSF-related metafield surfaced verbatim. Nothing hidden. If you spot data that looks wrong, let us know.

VSF score
71 / 100
Tier
Verified
Category
Diagnostics testing
Subcategory
cancer chronic screening
Last scored
Third-party certifications
None on record at time of scoring
Vendor
Medsitis
Product type
Test Kits
Tags
Medsitis, Shopify Collective

Every score is set from the published rubric, audit-logged, and rescored whenever new evidence emerges (published trials, updated labels, third-party testing releases). Every vendor is scored on the same criteria — no pay-to-play. See our editorial-independence disclosure for the full policy, including brands with an editorial relationship to this site.

View full details